Roche 公布 sefaxersen 治疗 IgA 肾病 III 期 IMAGINATION 研究中期阳性结果
Roche’s Announcement Regarding Sefaxersen (Announcement of Interim Analysis Results from the Phase III IMAGINATION Study)
Chugai 转述 Roche 9月23日发布的消息：全球 III 期 IMAGINATION 研究评估 sefaxersen 治疗 IgA 肾病，中期分析显示阳性结果，sefaxersen 显著降低蛋白尿。详细数据将在即将召开的医学会议上公布。
关注 sefaxersen 在 IgAN 的 III 期中期蛋白尿数据，后续完整数据读出与注册推进节奏值得跟踪。
TOKYO, September 24, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a media release on September 23, regarding positive results from the interim analysis of the global Phase III IMAGINATION study evaluating sefaxersen in IgA nephropathy.
The detailed data will be presented at an upcoming medical meeting.
Please refer to the link below for details of Roche’s media release:
Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
来源：Chugai 中外制药｜中外制药 · chugai-pharm.co.jp